OSA

jetcityimage/iStock Editorial via Getty Images Respiratory device makers ResMed (NYSE:RMD), and Philips (NYSE:PHG) traded lower on Friday after Eli Lilly (NYSE:LLY) said an FDA decision on a potential label expansion for its weight loss therapy tirzepatide against obstructive sleep apnea (OSA) is expected later this year. The announcement hurt theContinue Reading